<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159688">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01811394</url>
  </required_header>
  <id_info>
    <org_study_id>ISAC-01</org_study_id>
    <nct_id>NCT01811394</nct_id>
  </id_info>
  <brief_title>Ion Irradiation of Sacrococcygeal Chordoma</brief_title>
  <acronym>ISAC</acronym>
  <official_title>Hypofractionated Ion Irradiation (Protons or Carbon Ions) of Sacrococcygeal Chordoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <authority>Germany: Federal Office for Radiation Protection</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and feasibility of primary
      hypofractionated irradiation of sacrococcygeal chordoma with carbon ions or protons using
      the raster scan technique.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>safety and feasibility of hypofractionated irradiation in patients with sacrococygeal chordoma using ions (protons or carbon ions) in raster scan technique</measure>
    <time_frame>From date of treatment start until 12 months after treatment.</time_frame>
    <description>The evaluation is based on incidence of Grade 3-5 toxicity (NCI-CTC-AE) and/or discontinuation of the treatment for any reason. Endpoint is the proportion of treatments without Grade 3-5 toxicity (NCI-CTC-AE) up to 12 months after treatment and/or discontinuation of the treatment for any reason</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>local progression free survival (LPFS)</measure>
    <time_frame>From date of treatment start until the date of first documented progression  in MRI/CT scan assessed up to 12 months.</time_frame>
    <description>local progression free survival (LPFS) is determined from start of treatment until local progression in imaging (&gt;10% size increase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From date of treatment start until the date of death from any cause assessed up to 12 months.</time_frame>
    <description>Further objectives are overall survival (OS) from date of treatment start until the date of death from any cause assessed up to 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>From date of treatment start up to 12 months. Evaluation at treatment start, at the end of treatment and 12 months after treatment.</time_frame>
    <description>Quality of life (QoL) evaluated with EORTC-QLQ30 questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Exposure to Artificially Accelerated Beams of Ionized Particles Generated by Synchrotrons</condition>
  <arm_group>
    <arm_group_label>protons</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16x4GyE protons</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbon ions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16x4GyE carbon ions</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>protons</intervention_name>
    <arm_group_label>protons</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>carbon ions</intervention_name>
    <arm_group_label>Carbon ions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological confirmation of sacrococcygeal chordoma

          -  Karnofsky performance status â‰¥ 70%

          -  Patients age 18 - 80 years

          -  Macroscopic tumour (MRI)

          -  Written informed consent

        Exclusion Criteria:

          -  Lack of macroscopic tumour

          -  Tumor extension in craniocaudal direction &gt;16cm

          -  Metal implants at the level of the tumor which could influence the treatment planning

          -  Inability of the patient to lie quiet for at least 20 minutes (eg due to pain)

          -  Prior radiotherapy of the pelvic region

          -  Simultaneous participation in another trial that could influence the results of the
             study

          -  Active medical implants without treatment approveal at the time of ion irradiation
             (eg, cardiac pacemaker, defibrillator)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Matthias Uhl, Dr.</last_name>
    <phone>+49 6221 568201</phone>
    <email>Matthias.uhl@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Klaus Herfarth Herfath, Prof.Dr.</last_name>
    <phone>+49 6221 568201</phone>
    <email>Klaus.herfarth@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Heidelberg, Radiooncology, HIT</name>
      <address>
        <city>Heidelberg</city>
        <zip>69125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Uhl, Dr.</last_name>
      <phone>+49 6221 568201</phone>
      <email>Matthias.uhl@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Klaus Herfarth, Prof.Dr.</last_name>
      <phone>+49 6221 568201</phone>
      <email>Klaus.herfarth@med.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Klaus Herfarth, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 12, 2013</lastchanged_date>
  <firstreceived_date>March 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Heidelberg</investigator_affiliation>
    <investigator_full_name>Klaus Herfarth - Dr. J. Debus</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>sacral chordoma</keyword>
  <keyword>chordoma</keyword>
  <keyword>carbon ion therapy</keyword>
  <keyword>proton therapy</keyword>
  <keyword>hypofractionation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chordoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
